Table 2

Secondary outcomes

Primary prevention trialsCoronary artery disease trials
Trials/participants/events (n)RR (95% CI)I2 (%)Trials/participants/events (n)RR (95% CI)I2 (%)
Efficacy outcomesCardiovascular mortality8/49 685/23901.07 (0.95 to 1.21)27.35/37 589/18020.86 (0.74 to 1.00)55.7
Myocardial infarction8/46 682/10921.03 (0.91 to 1.15)0.05/29 893/23670.83 (0.72 to 0.97)60.0
Stroke9/47 546/15360.89 (0.73 to 1.09)52.96/38 049/9430.79 (0.66 to 0.94)36.6
Heart failure6/44 881/19030.90 (0.81 to 1.00)17.75/37 589/9570.76 (0.67 to 0.86)0.0
Safety outcomesHypotension-related AEs6/44 058/51411.71 (1.32 to 2.22)90.33/28 817/7931.63 (1.01 to 2.63)85.9
Renal impairment8/49 627/9921.20 (0.93 to 1.55)71.61/12 215/361.25 (0.65 to 2.41)
  • AEs, adverse events; RR, relative risk.